NA Vaccine Institute
NA Vaccine Institute is committed to developing innovative preventive and therapeutic drugs based on self-developed technology. Since its establishment in February 2018, it aims to create a healthier and happier world through new drugs with improved efficacy and reduced side effects, focusing on understanding the immune system and target diseases. The company strives to become a global pharmaceutical leader that benefits society by continuously developing next-generation medicines for disease prevention and treatment.
Industries
NA Vaccine Institute
Products
Defined nucleic-acid immune stimulant (TLR3/RIG-I agonist)
A homogeneous, high-purity nucleic-acid–based immune stimulant developed to activate TLR3 and RIG-I signaling, designed for stability, solubility and induction of Th1 and CTL responses; produced in GMP and non-GMP grades for use as a vaccine adjuvant or combination therapy component.
Peptide epitope vaccine platform (co-delivery)
A platform technology enabling co-delivery of peptide epitopes with an immune stimulant to elicit epitope-specific T-cell responses for cancer and chronic viral infection applications, with reported improved efficacy in preclinical tumor models and compatibility with combination therapies.
Pulmonary delivery vaccine approach for lung-resident immunity
A delivery approach combining vaccine antigen with an immune stimulant delivered to the lung to generate lung-resident memory CD4+ T cells and broad cross-reactive protection, positioned for universal influenza and booster applications.
Defined nucleic-acid immune stimulant (TLR3/RIG-I agonist)
A homogeneous, high-purity nucleic-acid–based immune stimulant developed to activate TLR3 and RIG-I signaling, designed for stability, solubility and induction of Th1 and CTL responses; produced in GMP and non-GMP grades for use as a vaccine adjuvant or combination therapy component.
Peptide epitope vaccine platform (co-delivery)
A platform technology enabling co-delivery of peptide epitopes with an immune stimulant to elicit epitope-specific T-cell responses for cancer and chronic viral infection applications, with reported improved efficacy in preclinical tumor models and compatibility with combination therapies.
Pulmonary delivery vaccine approach for lung-resident immunity
A delivery approach combining vaccine antigen with an immune stimulant delivered to the lung to generate lung-resident memory CD4+ T cells and broad cross-reactive protection, positioned for universal influenza and booster applications.
Services
Development and supply of immune stimulants and adjuvants
R&D, GMP production and commercial supply of immune stimulants and vaccine adjuvants in multiple formulation formats and supply grades.
Preclinical immunogenicity and efficacy evaluation
Preclinical testing services including immunogenicity (antibody and T-cell) assays and in vivo efficacy studies in tumor and infectious disease models.
Development and supply of immune stimulants and adjuvants
R&D, GMP production and commercial supply of immune stimulants and vaccine adjuvants in multiple formulation formats and supply grades.
Preclinical immunogenicity and efficacy evaluation
Preclinical testing services including immunogenicity (antibody and T-cell) assays and in vivo efficacy studies in tumor and infectious disease models.
Expertise Areas
- Vaccine and adjuvant development
- Immuno-oncology (cancer vaccines and combinations)
- Peptide-based T-cell vaccine platforms
- Mucosal/pulmonary vaccine delivery
Key Technologies
- TLR3 agonist immune stimulants
- RIG-I pathway agonists
- Peptide epitope co-delivery platform
- Peptide complexation without chemical conjugation